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Summary Prostaglandins may have both undesirable and desirable effects in malignant disease. Their
possible roles in breast cancer were studied by examining the relationships between different variables and the
amounts of prostaglandin-like material (PG-LM) extracted from 141 breast carcinomas. Univariate analysis
indicates a direct correlation with patient age and menopausal status, with a greater yield from cancers of
post- compared with pre-menopausal women. Tumours up to 2cm diameter yielded more PG-LM than those
measuring >2-5cm. Although there was also a direct correlation with bone metastasis near to the time of
surgery, this was because no positive bone scans occurred in patients whose tumours yielded little total PG-
LM (<16ng PGE2 equivalents per g tissue). Since tumour PG-LM did not predict later spread to bone, and
yields of > 16 ng g-' were similar in the positive and negative bone scan groups, tumour PG-LM appears to
be unimportant for skeletal metastasis. There was no obvious relationship of tumour PG-LM to the grade of
malignancy, tumour type, amounts of fibrous tissue (and therefore malignant cells), invasion of blood vessels
and lymphatics or presence of plasma cells. Multivariate analysis indicates that disease-free survival is longest
with an intermediate production of tumour total PG-LM. Of the 82 patients now dead, the cause was
attributed to metastatic disease in 69 cases. No relationship of PG-LM to the length of survival was seen with
univariate or multivariate analysis. However, when just the post-menopausal patients who died within the first
3 postoperative years were analysed, there was a highly significant inverse correlation between the tumour
total PG-LM and the time to death. The reason(s) for these different findings on overall survival compared
with just the patients who died are not understood, but the results may indicate that one or more other
variables must co-exist with a high tumour PG-LM to hasten death.
Many tumours can produce more prostaglandins (PGs) than
the normal tissues in which they arise (Bennett, 1979, 1982,
1988). Similarly, more prostglandin-like material (PG-LM),
assayed on rat gastric fundus which is most sensitive to
PGE2, was extracted from homogenates of human mammary
carcinomas than from benign tumours or macroscopically
normal breast tissue (Bennet et al., 1977). Various PGs and
related substances extracted from breast carcinomas were
identified by Stamford et al. (1983) using gas chromato-
graphy-mass spectrometry; the products were arachidonate,
12-hydroxy-eicosatetraenoate (12-HETE), thromboxane B2,
15-keto-l3,14-dihydro-TXB2, 6-keto-PGFJ,, 6,15-diketo-
PGF1,,, 615-diketo-13,14-dihydro-PGF1,,, PGD2, PGE2 and
PGF21,. Quantitative gas chromatography-mass spectrometry
showed substantial amounts of 6-keto-PGF, . and some
PGD2, PGE2 and PGF20,, with much higher yields of
arachidonate (Stamford et al., 1986). It might be expected
that these potent substances contribute to breast cancer, but
the problem is complex because PGs have numerous actions
that may produce both undesirable and desirable effects, and
because PGs are formed by both host and malignant cells in
the tumour (Bennett, 1979, 1982, 1988).
Several years ago we reported that the production of PG-
LM by human primary breast carcinomas was higher in
patients with scintigraphic evidence of skeletal metastases
and correlated with early death (Bennett et al., 1975, 1977).
This study, which closed in 1978 after being extended to 141
patients, confirms the higher median amount of PG-LM
from tumours of patients with positive bone scans. However,
this is because only negative scans occurred when the
tumour PG-LM production was very low. We also confirm
the correlation with early death, but we have now found that
it does not apply to later death or to premenopausal women.
Thus a high yield of PG-LM by the tumours is not
necessarily bad, and a low yield is not necessarily good:
indeed multivariate analysis indicates that the longest
disease-free survival is associated with an intermediate
production of tumour total PG-LM.
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Patients and methods
Samples of histologically confirmed malignant breast
tumours were obtained from 152 unselected women under-
going breast surgery in six south-east London hospitals
between August 1974 and January 1978. However, 11 were
excluded from all analyses: seven had a previous malignancy,
three had bilateral breast carcinomas and one patient was
irradiated preoperatively. This left a total of 141 patients,
but different numbers were available for various analyses, as
specified in the relevant sections. The carcinomas were
divided into three groups: infiltrating ductal carcinomas
(n = 106), intraduct (non-invasive, n=4) and miscellaneous
(n = 16, comprising seven mucinous, four anaplastic, two
tubular, one adenocarcinoma with squamous metaplasia, one
spheroidal cell carcinoma and one medullary carcinoma).
There were four unidentified tumours, and a further 11 cases
in which sections were not available.
Independent examinations of the 130 tumours for which
sections were available were made by two senior pathologists
who were unaware of the PG-LM data. Tumour size,
histological type, grade of malignancy, border of growth,
lymph node involvement, amount of cellular infiltration
around and in the tumour, predominant inflammatory cell
type, content of plasma cells, amount of fibrous tissue and
the invasion of blood vessels and lymphatics were recorded
where possible and scored. The histology was carried out on
the part of the tumour retained by the pathologists and is
therefore not necessarily representative of the separate
portion that was extracted.
All but one of the patients were staged clinically using the
TNM classification (stage I=Ti-2 NO MO; stage II=Tl-2
Ni MO; stage III=T3-4 NO-2 MO; stage IV=Tl-3 NO-2
MI. Forty-five patients (clinical stages I and II) were also
staged histologically.
Within 10-60min of tumour excision, a sample of the
malignant tissue provided by a pathologist was homogenised
in Krebs solution or acidified ethanol (Bennett et al., 1973,
1977) and extracted for PGs by the method of Unger et al.
(1971), which gives recoveries of at least 70%. Basal and
total PG-LM (total=basal+newly synthesised PG-LM) were
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bioassayed on rat gastric fundus strips against PGE2 as
described in the latter references. Basal values reflect the
amount of PG-LM present in the tissues at the time of
homogenisation, whereas total PG-LM reflects in addition
the new synthesis of PGs from precursors released during
homogenisation; the actual amount of the newly synthesised
PG-LM is 'total minus basal PG-LM', since apart from the
hydrolysis of PGI2 there is little or no degradation of PGs
during homogenisation. These values are expressed as ng
PGE2 equivalents per g wet weight tissue, and presented as
median values with semiquartile ranges in parentheses. In
125 cases the total, basal and synthesised tumour PG-LM
were all measured, but in the remaining 16 cases only total
PG-LM was determined because of insufficient tissue.
The first skeletal scintigraphy was carried out on 120
patients within 6 months of operation, and on 11 other
patients 9-36 months postoperatively, using 5-10mCi
99Tc-labelled ethanehydroxy-diphosphonate i.v. Fifteen
patients have been excluded from the main analysis because
the first scans were either before operation (1 month before
in three patients, 5 months before in one patient), or >6
months after surgery (11 patients). The remaining group,
scanned up to 6 months postoperatively, has been split into
those untreated before the first recurrence and those given
various types of therapy (see below). A further 125 scans on
66 of these patients were subsequently carried out at
intervals. Before disclosing the PG results, the scans were
interpreted by staff of our nuclear medicine department and
by surgeons. Recurrences and survival follow-up data were
obtained from medical records, the radiotherapy department,
general practitioners and the South Thames Cancer Registry.
Various postoperative treatments were given to 67 patients
before recurrent disease was detected, and 66 received none;
eight have been excluded because the information is not
available. The treatment consisted of cytotoxic chemotherapy
(usually methotrexate and melphalan), tamoxifen 10 or
20mg twice daily, non-steroidal anti-inflammatory drugs,
oophorectomy, anxiolytic/antidepressant drugs and/or radio-
therapy.
Patient survival was measured to the nearest month after
surgery (except for the death at 4 days). The times from
operation to this analysis are 90-131 months, and the
follow-up period extends to 124 months (median 58 months).
Statistics
The Mann-Whitney U test, Spearman rank correlation or %2
test with Yates' correction (all two-tailed) were used as
appropriate. Disease-free interval and patient survival were
analysed mainly using the method of Lee & Desu (1972)
(SPSS, London University Computer). Multivariate analysis
(BMDP, University of California, 1981) with Cox's
regression, which assesses the simultaneous influences of
several variables, was used to analyse disease recurrence and
patient survival. As there are numerous comparisons with
total, basal and synthesised PG-LM, for simplicity some are
not reported when P>0.1.
Results
Overall, the tumours from the six hospitals yielded similar
amounts of PG-LM.
PG-LM in relation to known prognostic variables
Histology Tumours of different types yielded mainly similar
amounts of PG-LM per g wet tissue (Table I), except
possibly the four intraduct carcinomas, which tended to
produce less.
There was no correlation of grade of malignancy with PG-
LM (n = 125), but the tumour grade correlated inversely with
survival (overall comparison P=0.049; Lee & Desu, 1972).
Amounts of fibrous tissue (and therefore conversely of
malignant tissue), scored as either 0 or + (together forming
Table I Amounts of PG-LM in different tumour types
Tumour type
Infiltrating
PG-LM ductal Intraduct Miscellaneous
Total 45(16-94)n= 106 22, 4, 29, 13 35(13-80)n=16
Synthesised 22(7-54)n=95 4, 11, 4 17(9-35)n =12
Basal 11(3-32)n=95 0, 18, 9 15(4-58)n=12
Amounts of PG-LM, expressed as ng PGE2 equivalents per g wet
weight of tumour, are shown as medians with semiquartile ranges in
parentheses or actual values for the intraduct carcinomas. P>0.1 for
all comparisons between tumour types, except for total PG-LM in
infiltrating ductal carcinomas and intraduct tumours where P= 0.09.
group 1, n =54) or + +(group 2, n= 72), did not correlate
with tumour PG-LM.
Malignant cells were found in the blood vessels and/or
lymphatics of 15/126 tumours. There was no correlation with
tumour PG-LM, contrary to the conclusion of the patho-
logist in our previous paper (Bennett et al., 1977) that of the
55 tumours then available (and included in the present
study) 41 showed spread of malignant cells into the blood
vessels and/or lymphatics. However, on re-evaluation, the
present pathologists found no vessel invasion in 24 formerly
considered positive, and they classified three as positive that
were previously considered to be negative.
There were 11 tumours with plasma cells and 115 without.
Basal tumour PG-LM was higher in the positive group
(P=0.05) but there was no correlation with the other PG-
LM measurements. Analysis of cellular infiltration, pre-
dominant inflammatory cell type and border of tumour
growth (infiltrating or pushing) in relation to PG-LM were
not feasible since in each case one group had very few
numbers.
Tumour size Tumour diameters were grouped as small,
medium and large (up to 2, 2-5 and >5cm, n=43, 50 and
38 respectively). The yield of total PG-LM from small
tumours, shown as the median ng PGE2 equivalents g-1
with the semiquartile range in parentheses, was 55 (22-
95)ng. This was greater than the 22 (10-74)ngg-1 from the
medium group (P=0.03), but mainly similar to the 38 (10-
92)ngg-1 from large tumours (P=0.3).
Lymph node status Of the 84 patients examined for
malignant lymph nodes, 35 had between 1 and 3, and 11
patients had at least 4. There was no obvious relationship to
the primary tumour PG-LM.
Clinical stage The numbers of patients in clinical stages I-
IV at presentation were respectively 67, 32, 30 and 11 (one
not staged). In general, less total PG-LM was obtained from
the tumours of stage I patients (stage I versus stages II, III
and IV, respectively, P=0.04, 0.09 and 0.39; stage I versus
the other stages combined P=0.02). Their amounts of
tumour total PG-LM were respectively 29(13-79), 59(27-
100), 68(21-113) and 54(26-75)ngg-1. Similar findings were
obtained when just the synthesised PG-LM was analysed,
but there was no relationship to basal PG-LM. As expected,
stage correlates inversely with the survival time (P= 0.008).
Menopausal status There were 91 post-menopausal patients
(last menstrual period at least 2 years before surgery) and 37
premenopausal women. The 13 patients of unclear status
have been omitted from the analyses. Tumours from the
post-menopausal patients yielded more total PG-LM than
those from the premenopausal subjects (44(16-101) versus
19(9-55)ngg-1; P<0.05).
Age Tumour total PG-LM shows some correlation with the
age at the time of surgery in all patients grouped together (r.
0.19; P=0.011, n=141), and in the post-menopausal group
alone (r, 0.19; P=0.034, n=91), but not in premenopausal
subjects (rS 0.11; P=0.25, n=37).270 A. BENNETT et al.
Prostaglandins in relation to disease recurrence
Bone metastasis near to the time of surgery The prevalence
of positive bone scans near to the time of breast surgery
correlates with total and synthesised PG-LM but not with
basal PG-LM, regardless of whether treated and untreated
patients are assessed separately or together (Table II). The
reason for the correlation is that no positive scans occurred
when the tumour total PG-LM yield was very low
(<16 ng PGE2 equivalents g- 1). Above this value there was
no relation to bone scans, and indeed the highest value was
in a scan-negative patient (Figure 1).
Of the 19 patients who were positive when first scanned
0-6 months postoperatively, 15 later presented with
symptomatic bone metastases; three patients were negative
when rescanned 12-52 months later and did not develop
symptomatic bone metastases; the other patient died 2
months postoperatively and her symptomatology is not
known.
Later recurrence in bone Forty-nine patients had no
treatment before disease recurrence, 46 received some form
of therapy (see Patients and methods) and in 21 cases the
information is not available. Of the 12 equivocal scans, 4/6
repeat examinations were positive within 13 months from
operation and two were negative within 37 months; the other
six were not scanned again. On retesting 48 patients
originally with negative scans, 18 became positive 7-64
months after operation, six were considered equivocal and 24
remained negative. The total PG-LM from the tumours of
the 18 patients who became scan-positive was lower than
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Figure 1 Scintigraphy for bone metastases. Each patient (0)
was assessed as positive (+ve), negative (-ve) or equivocal. The
different median values of tumour total PG-LM in the +ve and
-ve groups (P<0.02) occurred because there were no positive
scans when the PG-LM was <16 ng PGE2 equivalents g-.
Table II Breast tumour prostaglandins and bone scan evidence of
skeletal metastases
Bone scans Total Synthesised Basal
Treated and untreated patients
Positive 73(27-113)n= 19 32(21-86)n = 17 19(6-34) n = 17
Equivocal 74(33-120)n=9 51(27-129)n=7 18(9-43)n=7
Negative 40(13-88)n= 88 20(6-40)n=76 12(4-40)n =76
Untreated patients
Positive 72(19-98)n=12 34(19-74)n = 12 19(5-20)n= 12
Equivocal 74(65-120)n=5 51(47-108)n=5 18(12-23)n =5
Negative 36(11-74) n=37 19(3-40)n=32 18(4-33)n=32
These results are for the 116 patients scanned from 0 to 6 months
postoperatively. Some received the treatments described in the
Patients and methods section. Statistical probabilities of P>0.1 are
not reported. The results from all patients (treated and untreated)
were: total PG-LM, positive versus negative P=0.026; synthesised
PG-LM positive versus negative P=0.03; negative versus equivocal
P<0.03. With just the untreated patients, the statistical probabilities
for total PG-LM were: positive versus negative P=0.03, equivocal
versus negative P=0.036; for synthesised PG-LM positive versus
negative P=0.004; negative versus equivocal P=0.015.
from the 19 patients who were initially scan-positive, being
27(11-95) compared to 73(27-113) ngPGE2 equivalentsg -1
(P=0.026), but mainly similar to the 40(12-88)ngg-' for
the 88 negative-scan patients (P= 0.69). Other aspects relating
to bone are included in the following section.
The incidence of tumour recurrence at any single site At the
time of the last follow-up of all women regardless of
menopausal status, there was at least one recurrence in 86
patients (46 local, 57 bone and 21 visceral sites). Tumour
total PG-LM in the 48 patients with metastasis at only one
site (excluding patients initially stage IV) tended to be
highest with tumours that spread locally and lowest with
those that spread to the viscera (respectively 78(9-
103)ngg-1, n=19; and 29(4-74)ngg-1, n=8; P=0.09). The
21 tumours that metastasised to bone occupied the
intermediate position (total PG-LM 51(23-94)ngg-1). As
expected, the time to first recurrence correlates with time to
death (rs 0.64; P=0.001, n=67 excluding the 13 non-cancer
deaths and the two cancer deaths where no recurrence was
detected). The median recurrence time in bone was shorter
(12 months) than locally (26 months, P<0.001) or in the
viscera (26 months, P=0.038). The total, basal or
synthesised PG-LM did not correlate with the time to first
recurrence (up to 83 months, P>0.28) or predict metastasis.
However, when only those patients with recurrent disease
were analysed, early recurrence (within 18 months) regardless
of site tended to correlate inversely with the primary tumour
total PG-LM (P=0.06). When only the post-menopausal
women were examined, this correlation increased (r, -0.5;
P=0.016, n=20). In contrast, with the small group of
premenopausal women there was a weak positive correlation
(rs 0.39; P=0.14, n=8).
Disease-free survival In order to examine further whether
there is any relationship of tumour PG-LM to disease-free
survival, the time to recurrence (including death without
detected recurrence) was analysed further by dividing the
patients into groups whose tumour total PG-LM was above
or below the median value of 43 ngg-1, and into three equal
groups of low, intermediate and high total PG-LM
(respectively up to 20, 20-80 and >80ng PGE2 equivalents
per g tumour). The patients in the intermediate group have a
median disease-free survival of 53.3 months, compared with
27.5 months in the high group (P=0.046; Lee & Desu
analysis) and 26.5 months in the low group (P=0.1 1). This
finding is mainly similar to the multivariate analysis below
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Patient survival
Allpatients Of the 82 deaths (58 post-menopausal, 17
premenopausal and seven of unclear status), 69 were
reported as due to cancer and 13 were attributed to other
causes. Survival curves (data from both dead and alive
patients) were similar when the patients were grouped above
or below the median tumour total PG-LM value, or into
low, intermediate or high total tumour PG-LM groups as
above (Figure 2). Tumour PG-LM values of the 63 patients
who survived 6 years or more are distributed similarly above
and below the median value for all patients.
However, on analysing just the patients dying within 3
years of surgery (a time point suggested by the data and
used here for hypothesis generation), there is a highly
significant inverse correlation with tumour total PG-LM for
the 39 dying from cancer (r, -0.55) and for the 46 deaths
from all causes (r, -0.49) (both P<0.001; Figure 3). The
relationship does not hold after the 3-year period.
Premenopausal women The median survival time was 31
months. There was a weak trend for a positive correlation
between total PG-LM and time to death (all reportedly from
cancer) in the 17 premenopausal patients who have now died
(P=0.11), and in the 10 patients dying within 3 years
(P=0.21; Figure 4a). Survival curves (i.e. including alive and
dead patients) were similar in patients with total, basal or
synthesized PG-LM values above and below their respective
median values, or divided into low, medium and high groups,
except that survival tended to be longest with the highest
total PG-LM (P=0.09).
Post-menopausal patients As with the premenopausal
women, the median survival time was 31 months. However,
unlike this group, the time to death up to 3 years post-
operatively showed striking inverse correlations with total,
basal and synthesised tumour PG-LM (respectively r, -0.6;
P=0.001, n=34; Figure 4b; r,-0.51; P=0.002, n=30;
rs-0.42; P=0.01, n=30). After the 3-year period, there was
no relationship between the total PG-LM and time to death
(rs-0.049; P=0.36, n=56).
Because of the striking relationship of PG-LM to early
death, we examined several variables for possible differences
between the 35/91 (38%) of post-menopausal women dying
within 3 years compared with the 62% surviving longer
(Table III). Of those living longer, more had stage I tumours
and less were stage IV; more had grade I tumours; re-
currence occurred later with more frequent local spread and
less in bone. There was little or no difference in the initial
bone scan finding, tumour PG-LM, age at the time of
surgery, lymph node involvement, tumour size, additional
treatment, histological type or amounts of fibrous tissue
(Table III).
Multivariate analysis offactors that may affect disease
recurrence and patient survival
Only those variables of proven prognostic value were
included (age, bone scan result and stage), to avoid the
problem of multiple significance testing and because of some
missing data. Menopausal status was not added as it
contributes to the included variable of age. Tumour size and
nodal status were not included partly because they
contribute to stage and partly because the results were not
available for all patients. Tumour grade was omitted because
of its low contribution to prognosis in the presence of the
other variables analysed. Pathological staging was used in
preference to clinical staging whenever possible, since it is
more accurate. Table IV shows the variables included in the
analysis; none of them interacted. The values given below
are followed by the 95% confidence limits in parentheses.
Disease-free interval In general agreement with the Lee &
Desu analysis, the intermediate group experienced 50% (28-
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Figure 2 Patient survival was similar in the groups with low
(mmii), medium (,,,,) or high () amounts of tumour total
PG-LM (respectively up to 20, 20-80 and >80ngPGE2
equivalents per g tumour).
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Figure 3 The time to death of all patients (cancer death 0,
n=69; non-cancer death 0, n= 13) is inversely related to the
tumour total PG-LM up to 3 years postoperatively (P<0.001),
but not subsequently.
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Figure 4 The time to death of premenopausal patients up to 3
years postoperatively shows, if anything, a weak correlation with
tumour total PG-LM (P=0.21; a). In contrast, the post-
menopausal patient deaths up to 3 years postoperatively are
inversely related to the tumour total PG-LM (P<0.001; b).
90% confidence limits) of the hazard in the low total PG-
LM group (P<0.05), and 55% (31-98%) of that in the high
group (P<0.05). There was no relationship of PG-LM to
just the bone scan data.
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Table III Variables in post-menopausal patients surviving for up
surgery compared with those living longer
to 3 years after breast
Survival up to P value
3 years Survival >3 years (Mann-Whitney or X2)
Number of patients 35/91 (38%) 56/91 (62%)
Thmour PG-LM (ngPGE2 equiv. g-1)
Total 40(16-88)n=35
Basal 8( 3-24)n=31
Synthesised 22( 7-54) n=31
Tumour stage
I
II
III
IV
Tumour grade
1
2
3
Tumour size
<2cm
2-5cm
>5cm
Histol. type
Infiltrating
Intraduct
Others
Fibrous tissue
0 or +
++
Positive lymph nodes
0
1-3
4+
Recurrence (months)b
Spreadb
Local
Visceral
Bone
Spread to only one sitec
Local
Visceral
Bone
9/35(26%)
8/35(23%)
11/35(31%)
7/35(20%)
6/34(18%)
22/34(64%)
6/34(18%)
9/30(30%)
17/30(57%)
4/30(13%)
28/33(85%)
1/33( 3%)
4/33(12%)
16/33(48%)
17/33(52%)
7/24(29%)
12/24(50%)
5/24(21%)
11(9-15) n=20
7/29(24%)
18/29(62%)
4/29(14%)
3/15(20%)
4/15(27%)
8/15(53%)
First bone scan
Negative 18/30(60%)
Equivocal 6/30(20%)
Positive 6/30(20%)
Age at surgery (years) 68(59-74) n =35
Non-surgical postoperative therapy
Drugs 3/35( 8%)
Radiotherapy 10/35(29%)
Radiotherapy + drugs 6/35(17%)
None 16/35(46%)
48(16-94)n=56
12( 4-29)n=47
28( 9-65)n=47
33/55(60%)'
7/55(13%)
14/55(25%)
1/55( 2%)
21/49(43%)
21/49(43%)
7/49(14%)
21/40(53%)
14/40(35%)
5/40(12%)
41/50(82%)
1/50( 2%)
8/50(16%)
22/50(44%)
28/50(56%)
16/30(53%)
11/30(37%)
3/30(10%)
39(26-51) n=22
15/26(58%)
7/26(27%)
4/26(15%)
10/16(62%)
3/16(19%)
3/16(19%)
41/52(79%)
3/52( 6%)
8/52(15%)
65(57-74) n=56
9/52(17%)
12/52(23%)
2/52( 4%)
29/52(56%)
Compared with the patients living up to 3 years postoperatively, the longer surviving
patients more often had tumours of a lower stage or grade and a later recurrence. There was
little or no relationship to the histological type, amount of fibrous tissue (and therefore
conversely of malignant tissue), initial bone scan finding, tumour PG-LM, age at surgery,
lymph node status, tumour size or non-surgical treatment.
aOne patient not staged; bregardless of the number of recurrence sites per patient; cpatients
with recurrence at only one site, excluding stage IV.
Survival The group with intermediate total PG-LM showed
at most a weak tendency to survive longer than the low and
high PG-LM groups. The hazard for the intermediate group
was 66 (38-115)% of that for the low group (P=0.16), and
79 (44-143)% of that for the high group (P=0.44).
We have confirmed that human mammary carcinomas can
usually produce substantial amounts of prostaglandin-like
material (PG-LM), although we do not know the relative
0.92(MW)
0.49(MW)
0.45(MW)
0.0019(x2)
0.052(x2)
0.85(x2)
0.18(X2)
<0.0001 (MW)
0.02(X2)
<0.05(X2)
0.096(X2)
0.58(MW)
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Table IV The probability values associated
with the prognostic variables in the
multivariate analysis of disease recurrence
and survival
Variable Recurrence Survival
Bone scan 0.001a 0.24
Stage 0.012b 0.026
Total PG-LM 0.035 0.033
Age 0.77 0.36
All the factors shown were included in the
regression model (see Gore et al., 1984)
because of their possible importance as
prognostic indicators. The analysis of
disease-free survival excludes patients with
positive bone scans and stage IV disease.
aEquivocal versus negative; bexcluding
stage IV disease.
contributions from malignant and host cells. Many factors
hamper the interpretation of our results, including the
problems of measuring and identifying the source of tumour
PG-LM. The measurement problem would be less with the
current better methods, but only bioassay was available to us
when our study began, and various important prostanoids
such as PGI2 and thromboxane A2 had not yet been
discovered. Our bioassay is most sensitive to PGE2 (Bennett
et al., 1980), and the measurements of tumour PG-LM
probably reflect mostly this compound. However, breast
tumours can produce several different PGs and related
substances (Stamford et al., 1983). Indeed, the amount of
PGF2., to which bioassay is about 10 times less sensitive
(Bennett et al., 1980), was similar to that of PGE2 (Fulton et
al., 1982; Watson et al., 1984).
A simple relationship between cancer and PGs is unlikely
because these numerous substances can have diverse
(sometimes even opposite) effects on cell proliferation, dif-
ferentiation, host defence and metastasis, etc. (Bennett, 1979,
1982, 1989). Furthermore, some PGs are involved in
inflammation, which has a variable effect on tumour spread,
a small inflammatory reaction causing enhancement and a
large one causing inhibition (Van den Brenk et al., 1974).
Prostaglandins in relation to known prognostic variables
Univariate analysis shows that tumour PG-LM correlates
directly with patient age, menopausal status and incidence of
positive bone scintiscans near to the time of surgery, but
inversely with tumour size. The bone aspects were an
important reason for starting the study, and are dealt with
first.
Bone metastasis We previously reported that breast cancers
of patients whose isotopic bone scans were positive near to
the time of surgery yielded a higher median amount of total
PG-LM than the negative group (Bennett et al., 1977). The
same is true in the present larger study, which incorporates
the previous results, but the correlation occurs only because
there were no positive initial bone scans in patients whose
tumours yielded very low amounts of PG-LM (<16ngg-1,
Figure 1). Above this value the tumour PG-LM values are
similar in the positive and negative groups. Furthermore, the
tumour PG-LM was not related to subsequent metastasis to
bone. Thus tumour PGs seem to be unimportant in the
spread of tumour to bone.
Even though breast carcinomas may release PGs into the
blood (Stamford et al., 1980), the concentrations are
probably insufficient to resorb bone, particularly since any
PGE and F compounds would be mainly inactivated during
passage through the pulmonary circulation (Ferreira & Vane,
1967). The tumours may also release PGI2 (Demers et al.,
1979), another potent bone resorber (Ali et al., 1979), but
although PGI2 survives the pulmonary circulation (Dusting
et al., 1978) and is sufficiently stable for some to reach the
skeleton, amounts needed to affect bone would presumably
exceed those causing profound hypotension. Thus if PGs
have any role as resorbing agents in bone metastasis, it is
probably only those formed locally by the metastasised cells
that are involved. Our multivariate analysis, and studies with
PG synthesis inhibitors, also argue against a role for PGs in
bone metastasis. Although indomethacin can reduce some
other malignant hypercalcaemias (Seyberth et al., 1975), it
did not affect hypercalcaemia in breast cancer (Coombes et
al., 1976), and benorylate did not affect the skeletal spread
of breast cancer (Powles et al., 1980). However, we must
take care before coming to a firm conclusion. PGs in vivo
can, unlike in vitro, cause bone formation (Ueda et al.,
1980), and cyclo-oxygenase inhibitors may increase the meta-
bolism of PG precursors into lipoxygenase products (Higgs
et al., 1980), some of which potently resorb bone in vitro
(Meghji et al., 1988). Furthermore, skeletal scans are not
always reliable indicators of bone metastases (Coombes et
al., 1983), and this might explain why a few of our scan-
positive patients were negative on subsequent retesting.
Menopausal status Cancers from post-menopausal women
yielded more PG-LM compared with the premenopausal
group. This agrees with Fulton et al. (1982) who obtained
more PGE2 from tumours of post-menopausal women
compared with those who were pre- or perimenopausal.
However, Watson et al. (1984) found similar yields of both
PGE2 and PGF2,-
Age Overall, the breast tumour total PG-LM correlates
with age. Similar trends were seen for microsomal PGE2
formation (Rolland et al., 1980) or for PGF2a production
(Vergote et al., 1985), but Kibbey et al. (1979) found no
relationship to PGE2. Fulton et al. (1982) obtained no
correlation of PGE2 with age in just the post-menopausal
women, whereas we did so with PG-LM in this group but
not in premenopausal subjects.
Tumour size Overall, the tumour size correlated inversely
with PG-LM production, in agreement with Rolland et al.
(1980) who measured microsomal PGE2 formation from
added arachidonic acid, with Fulton et al. (1982) who
measured endogenously formed PGE2, and with Vergote et
al. (1985) who found a similar tendency with PGF2a. In
contrast, Karmali et al. (1983) and Watson et al. (1987)
found no relationship between PGs and tumour size. Our
inverse correlation with PG-LM was due mainly to the
results with only the small and medium tumours. Although
ischaemia and necrosis of the central part of larger tumours
might affect the formation of PGs, we washed away the
necrotic tissue before extraction.
Variables showing no relationship to PG-LM It must be
stressed that the samples for histology or extraction were
from different parts of the tumour, and this might explain
lack of correlation. Grade of malignancy, the main
histological variable that influences prognosis (Bloom &
Richardson, 1957), did not correlate with PG-LM. Fulton et
al. (1982) found that PGE2 and PGF2. correlated with the
grade of malignancy, but in contrast Vergote et al. (1985)
obtained more PGF2a, from differentiated tumours than from
undifferentiated tumours. -
We previously reported a correlation between tumour PG-
LM and the histological presence of malignant cells in the
blood vessels, lymphatics and lymph nodes (Bennett et al.,
1977). Furthermore, Rolland et al. (1980) concluded that
tumours whose microsomes produced highest amounts of
PGE2 from added arachidonic acid were most malignant.
Unfortunately, our new histological assessment differs from
the previous one, and argues against a relationship between
PGs and tumour spread into vessels. Since pathologists vary
in their histological assessment of tumour grade (Delides et274 A. BENNETT et al.
al., 1982) and malignant cells in blood vessels (4.7-52%;
Fisher et al., 1975; Borah et al., 1980; Weigand et al., 1982),
this argument is not settled. Furthermore, perhaps a tumour
total PG-LM production of at least 16ngg-1 aids the
dispersion of malignant cells, as judged by the absence of
positive bone scans near to the time of surgery in patients
whose primary tumours produced very low amounts of total
PG-LM.
The tumour type seems to bear at most a weak relation-
ship to the PG-LM yield. However, the four intraduct (non-
invasive) carcinomas produced comparatively little PG-LM,
consistent with the low contents of PGF2e in comedo
(intraduct) tumours (Vergote et al., 1985).
Amounts of fibrous tissue (and therefore conversely of
malignant cells), or the presence of plasma cells, did not
correlate with PG-LM. With other variables there were
insufficient numbers in one group to evaluate the relation-
ship of PG-LM to cellular infiltration, the predominant
inflammatory cell type, or border of tumour growth.
We did not measure steroid receptors in our present
experiments, but our separate study (Wilson et al., 1980)
indicates that the oestrogen receptor content and breast
tumour PG-LM are independent variables. Watson et al.
(1984, 1987) obtained no correlation between PGE2 or
PGF2a and oestrogen or progesterone receptors, but
Campbell et al. (1982) found that oestrogen receptor-positive
cancers produced more PGE2 than the receptor-negative
tumours, and Vergote et al. (1985) found a correlation
between PGF2. and both the oestrogen and progesterone
status. Karmali et al. (1983) reported that tumours with
progesterone receptors tended to produce more PGI2 than
did receptor-negative tumours; no relationship to other PGs
was found, but thromboxane production was lower when
oestrogen receptors were present. Fulton et al. (1982) found
no relationship of tumour PGE2 or PGF2a to progesterone
receptors but there was a variable association with oestrogen
receptors.
Disease-free survival
Tumour PG-LM tends to correlate inversely with recurrence
at any site up to 18 months postoperatively (P=0.06), but
not subsequently. This is consistent with an absence of
positive bone scans with tumours yielding low amounts of
total PG-LM. However, multivariate analysis indicates that
the longest disease-free interval occurs with an intermediate
tumour total PG-LM. Thus a high production of tumour
PG-LM is not necessarily bad. Vergote et al. (1985) found
that a good prognosis was associated with a high yield of
tumour PGF2a,, but the biological effects of this PG are
often different, and sometimes opposite, to those of PGE2.
In contrast, Watson et al. (1987) found no relationship of
PGE2 and PGF2a to the disease-free interval.
Survival
When 25 patients had died and the follow-up time was 1.5-
54 months, we reported an inverse correlation between total
PG-LM and the time to death (Bennett et al., 1979).
Similarly in the present study, which includes the patients in
the previous analysis, there is a highly significant inverse
correlation of tumour total PG-LM with the time to death
within the first 3 postoperative years. However, we have now
found that this correlation occurs only in the post-
menopausal women.
The difference between the findings with just the dead
patients, compared with the overall survival which includes
the alive and dead patients, is a puzzle. Perhaps a high
tumour PG-LM leads to early death only when associated
with undetermined factor(s), one of which might be
oestrogen receptors whose absence carries a poor prognosis
(Howat et al., 1985); prognosis might be best with oestrogen
receptor-positive tumours that produce an intermediate
amount of tumour PG-LM. The 3-year cut-off point is one
suggested by the data, since there is no relationship of PG-
LM to survival after this time. This study has therefore
generated the hypothesis that PG-LM may be a factor in
early death from breast cancer. Other studies that are
already in progress will be able to test this possibility.
In summary, our main conclusions are that breast tumour
PG-LM production (which probably represents mostly
PGE2) seems unlikely to be important in metastasis to bone
or other sites, or to overall patient survival. Nevertheless, a
striking finding is that post-menopausal women dying within
3 years of surgery show a highly significant inverse
correlation between tumour total PG-LM and time to death.
The reason for this is not understood but, if it is not an
artefact, it presumably requires the presence of one or more
other variables for the early prognosis to be bad. It is also
interesting that no positive bone scans were found near to
the time of surgery in patients whose tumours produced low
amounts of PG-LM. However, a high production of PG-LM
by the tumour is not necessarily bad, and the disease-free
survival is longest in women whose breast tumours produced
intermediate amounts of total PG-LM.
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